OncoMatch/Clinical Trials/NCT03089554
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Is NCT03089554 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Therapeutic Intervention for cancer.
Treatment: Therapeutic Intervention — This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received:
Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.
Cannot have received: chemotherapy
Exception: within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: radiotherapy
Exception: within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Markey Cancer Center, University of Kentucky · Lexington, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03089554 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify